Sanofi chooses Biomunex Pharmaceuticals for antibody development licensing agreement

By Sophie Bullimore 18-Jan-2019

Two Paris-based companies have signed an agreement for development of bi- and multi-specific antibodies

Sanofi and Biomunex Pharmaceuticals have signed a licencing agreement, the first of its kind for Biomunex.

The agreement gives Sanofi access to Biomunex' technology for bi- and multi-specific antibody therapeutics and will be solely responsible for the R&D, manufacturing and commercialisation activities.

Biomunex will receive an initial payment and will then be eligible to receive further payments upon developmental milestones.

Sign up for your free email newsletter

Commenting on the agreement, Pierre-Emmanuel Gerard MD, Biomunex founder and CEO, said it was: “the starting point for our collaboration strategy with pharmaceutical companies to discover and develop cutting-edge bi- and multi-specific antibodies, giving patients new treatment options.”